



The U.S.P.T.O official mailroom stamp affixed hereto acknowledges receipt of the items listed below.

Applicant Collins et al.

Serial No. 09/690,353

Title Cobalamin Conjugates Useful as Imaging Agents and Therapeutic Agents

Papers Submitted: Information Disclosure Statement; PTO Form 1449 and copies of cited references

Attorney CGS/ds
Date Mailed April 3, 2001
Docket 07959.105030



DOCKET NO. 105036
ATTORNEY CGS
DUE DATE NIS
DATE DOCKETED 4/12/01 VSH



PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 09/690,353 Confirmation No. 2345
Applicant : Collins *et al.*
Filed : October 16, 2000
Title : Cobalamin Conjugates Useful As Imaging and Therapeutic Agents
TC/A.U. : 1616
Examiner : Dameron Levest Jones

Docket No. : 07959.105030 (COP 1003US)
Customer No. : 20786

Mail Stop Issue Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


**COMMUNICATION UNDER 37 C.F.R. § 1.312 AND
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

This Communication is submitted under 37 C.F.R. § 1.312 after allowance in response to Notice of Allowability mailed November 12, 2003.

The enclosed 1449 Form list references CQ, CT, CCF, which were filed with the Information Disclosure Statement on April 3, 2001 in the above-referenced application. The Patent Office acknowledged receipt of these references in a postcard stamped by the Patent Office on April 6, 2001. A copy of the postcard is enclosed. These three references were crossed out by the Examiner on the 1449 Form returned with the Office Action dated June 3, 2002. Applicants submit a Supplemental Form PTO-1449 listing the three cited references, and a copy of each reference. Applicants respectfully request that the Examiner initial the enclosed 1449 Form to make these references of record.


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on February 12, 2004.


Tisha Hardrick

Appl. No. 09/690,353
Comm. Under 37 C.F.R. § 1.312 and
Supplemental Information Disclosure Statement
dated February 12, 2004
Reply to the Notice of Allowance


No fee is believed to be due in connection with this Communication Under 37 C.F.R. § 1.312. The Commissioner is hereby authorized to charge any fees or credit any overpayment to our Deposit Account No. 11-0980.

Respectfully submitted,



Madeline I. Johnston, Esq.
Reg. No. 36,174

Date: February 12, 2004
King & Spalding, LLP
45th Floor
191 Peachtree Street, N.E.
Atlanta, Georgia 30303
Office: (404) 572-4600
Fax: (404) 572-5145

**LIST OF INFORMATION DISCLOSED BY APPLICANT***(Use several sheets if necessary)*

ATTY. DOCKET NO.	SERIAL NO.	FILING DATE
07959.105030 (COP 1003 US)	09/690,353	October 16, 2000
APPLICANT		GROUP
Collins <i>et al.</i>		1616

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	NAME	TRANSLATION	
					YES	NO

OTHER REFERENCES *(Including Author, Title, Date, Pertinent Pages, Etc.)*

AA	Finkler, <i>et al.</i> , Nature of the Relationship between Vitamin B ₁₂ Binding and Cell Uptake, <u>Archives of Biochemistry and Biophysics</u> , 120, 79-85 (1967).
AB	Hall, <i>et al.</i> , Cyclic Activity of the Receptors of Cobalamin Bound to Transcobalamin II, <u>Journal of Cellular Physiology</u> , 133, 187-191 (1987).
AC	Rappazzo, <i>et al.</i> , Transport Function of Transcobalamin II, <u>The Journal of Clinical Investigation</u> , 51:1915-1918 (1972)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.